Contents hide 1 About Mirdametinib 1.1 Neurofibromatosis Type 1 (NF1) 1.1.1 Body surface area (BSA) dosing 1.2 Dosage Modifications 1.2.1 Recommended dose reductions 1.2.2 Ocular toxicity 1.2.2.1 Grade 1 or 2 1.2.2.2 Grade 3 or 4 1.2.2.3 Symptomatic retinal pigment epithelium detachment (RPED) 1.2.2.4 Retinal vein occlusion (RVO) 1.2.3 Left ventricular dysfunction 1.2.4 Dermatologic toxicity 1.2.5 Other adverse reactions 1.2.6 Renal impairment 1.2.7 Hepatic impairment About Mirdametinib Mirdametinib inhibits the MEK1 and MEK2 proteins within the MAPK pathway, which regulates cell growth and survival. In people with NF1, these pathways are dysregulated, leading to benign tumors on the nerves. Mirdametinib … Continue reading LuciMird (Mirdametinib)